Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acalabrutinib - Acerta Pharma/AstraZeneca

Drug Profile

Acalabrutinib - Acerta Pharma/AstraZeneca

Alternative Names: ACP-196; CALQUENCE

Latest Information Update: 14 Jun 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acerta Pharma
  • Developer Acerta Pharma; AstraZeneca; Biologics Inc
  • Class Anti-infectives; Antineoplastics; Antirheumatics; Benzamides; Heavy metals; Imidazoles; Pyrazines; Pyridines; Pyrrolidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma; Chronic lymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Phase III Diffuse large B cell lymphoma
  • Phase II B-cell lymphoma; Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Richter's syndrome; Waldenstrom's macroglobulinaemia
  • Phase I/II B-cell prolymphocytic leukaemia; Follicular lymphoma; Glioblastoma; Multiple myeloma
  • Phase I Infections; Non-Hodgkin's lymphoma
  • Discontinued COVID 2019 infections; Haematological malignancies; Rheumatoid arthritis

Most Recent Events

  • 07 Jun 2021 Final efficacy and adverse events data from the phase III ELEVATE-RR trial in Chronic lymphocytic leukaemia released by Acerta Pharma
  • 07 Jun 2021 Long term efficacy and adverse events data from the phase III ELEVATE-TN trial in Chronic lymphocytic leukaemia released by Acerta Pharma
  • 04 Jun 2021 Additional adverse events data from the phase III ELEVATE-RR trial in Chronic lymphocytic leukaemia presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top